P300 amplitude as a possible correlate of frontal degeneration in schizophrenia

Schizophrenia Research
M Martín-LoechesT Palomo

Abstract

The existence of neurodegeneration is a debated issue in schizophrenia research. The P300 component of event-related electrical potentials (ERP) has been related to the different degree of damage to gray and white matter. This study explores the possible relationship between P300 amplitude and/or latency and the existence of degenerative processes in schizophrenia, by assessing its correlation with volume of sulcal CSF and duration of illness, as transversal indicators of neurodegeneration. Nineteen patients (14 males, 5 females) and 13 controls (6 males, 7 females) were studied with MRI and electrophysiological records (P300). The possible influence of sex and age at the time of the exploration was statistically controlled in both groups. The results show a significant negative correlation between P300 amplitude and prefrontal CSF volume in the patient group. A lower though still significant correlation was also found between P300 amplitude and duration of illness, whereas no correlation was found in the control group. These results support the hypothesis that P300 amplitude may be interpreted as a marker of neurodegeneration in schizophrenia.

References

Jan 1, 1992·Schizophrenia Bulletin·R M MurrayS W Lewis
Jun 1, 1994·Biological Psychiatry·W K StrikK Maurer
Jan 15, 1994·Biological Psychiatry·J M FordA Pfefferbaum
Jan 1, 1996·Journal of Computer Assisted Tomography·N C AndreasenW T Yuh
Oct 20, 1998·Biological Psychiatry·K L CoburnN C Moore
Jan 23, 1999·Biological Psychiatry·T Frodl-BauchU Hegerl
Jun 8, 1999·Clinical EEG (electroencephalography)·V KnottT Mendis
Sep 4, 1999·Neuropsychobiology·T Frodl-BauchU Hegerl
Nov 11, 1999·Psychophysiology·J M Ford
Jan 11, 2000·Journal of Psychiatric Research·L E DeLisi
Mar 11, 2000·Lancet·D Blackwood
Feb 15, 2012·Nature Reviews. Cardiology·Bas L van der HoevenVictoria Delgado

❮ Previous
Next ❯

Citations

Mar 9, 2005·Archives of General Psychiatry·Rajendra A MoreyAysenil Belger
Aug 13, 2004·Journal of Affective Disorders·Charalabos C PapageorgiouGeorge Christodoulou
Mar 29, 2003·International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology·Jijun WangChikara Ogura
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Charalabos PapageorgiouGeorge N Christodoulou
Apr 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Charalabos PapageorgiouGeorge N Christodoulou
Apr 26, 2003·Psychiatry Research·Lara L Davidson, R Walter Heinrichs
Oct 29, 2003·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Jijun WangChikara Ogura
Jan 6, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Christoph MulertDan Rujescu
Feb 9, 2011·Journal of Psychiatry & Neuroscience : JPN·Paolo Fusar-PoliPhilip McGuire
Apr 14, 2006·Psychopharmacology·Andres NeuhausJürgen Gallinat
Jan 11, 2016·Journal of Neuroscience Research·Farid MotlaghHussain Habil
Sep 29, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·V MolinaM Desco
Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Charalabos C PapageorgiouAndreas D Rabavilas
Apr 6, 2005·Psychiatry Research·Andres PosadaNicolas Franck
Apr 1, 2015·Annals of the New York Academy of Sciences·Robert E FeatherstoneSteven J Siegel
Sep 28, 2016·CNS Spectrums·Estêvão Scotti-Muzzi, Osvaldo Luis Saide
Jun 19, 2009·Clinical EEG and Neuroscience·Silvana GalderisiNash Boutros
Jun 8, 2018·Frontiers in Computational Neuroscience·Fali LiPeng Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here